Allergic Bronchopulmonary Aspergillosis

Journal of Allergy and Clinical Immunology: In Practice

Volumn 2, Issue 6, 2014, Pages 703-708

  Greenberger, Paul A ^a   Bush, Robert K ^b   Demain, Jeffrey G ^c   Luong, Amber ^d   Slavin, Raymond G ^e   Knutsen, Alan P ^e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allergic; Aspergillosis; Asthma; Azole; Bronchopulmonar; IgE; Mycosis

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; BECLOMETASONE DIPROPIONATE; CORTICOSTEROID; IMMUNOGLOBULIN E; ITRACONAZOLE; KETOCONAZOLE; METHYLPREDNISOLONE; OMALIZUMAB; POSACONAZOLE; PREDNISOLONE; PREDNISONE; PYRROLE DERIVATIVE; VORICONAZOLE; BIOLOGICAL MARKER;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ARTICLE; ASPERGILLUS FUMIGATUS; DIAGNOSTIC PROCEDURE; DISEASE EXACERBATION; EXPOSURE; GENETIC RISK; HEALTH SURVEY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGIST; IMMUNOPATHOLOGY; NONHUMAN; RECOMMENDED DRUG DOSE; SYMPTOM; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; BLOOD; CLINICAL PRACTICE; GENETIC PREDISPOSITION; GENETICS; HEALTH CARE SURVEY; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PREDICTIVE VALUE; RISK FACTOR; STANDARDS; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ALLERGY AND IMMUNOLOGY; ANTIFUNGAL AGENTS; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; BIOMARKERS; GENETIC PREDISPOSITION TO DISEASE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; IMMUNOGLOBULIN E; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84920101123     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2014.08.007     Document Type: Article

References (53)

1. Denning D.W., Pleuvy A., Cole D.C. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol 2013, 51:361-370.
2. Greenberger P.A. When to suspect and work up allergic bronchopulmonary aspergillosis. Ann Allergy Asthma Immunol 2013, 111:1-4.
3. Hinson K.F.W., Moon A.J., Plummer N.S. Bronchopulmonary aspergillosis: a review and report of eight new cases. Thorax 1952, 7:317-333.
4. Greenberger P.A. Allergic bronchopulmonary aspergillosis and fungoses. Clin Chest Med 1988, 9:599-608.
5. Akiyama K., Takizawa H., Suzuki M., Miyachi S., Ichinohe M., Yanagihara Y. Allergic bronchopulmonary aspergillosis due to Aspergillus oryzae. Chest 1987, 91:2856.
6. Elliott M.W., Newman-Taylor A.J. Allergic bronchopulmonary aspergillosis. Clin Exp Allergy 1997, 27(Suppl1):55-59.
7. Chowdhary A., Agarwal K., Randhawa H.S., Kathuria S., Gaur S.N., Najafzadeh M.J., et al. Arare case of allergic bronchopulmonary mycosis caused by Alternaria alternata. Med Mycol 2012, 50:890-896.
8. McAleer R., Kroenert D.B., Elder J.L., Froudist J.H. Allergic bronchopulmonary disease caused by Curvularia lunata and Drechslera hawaiiensis. Thorax 1981, 36:338-344.
9. Akiyama K., Mathison D.A., Riker J.B., Greenberger P.A., Patterson R. Allergic bronchopulmonary candidiasis. Chest 1984, 85:699-701.
10. Arora A., Huffnagle G.B. Immune regulation during allergic bronchopulmonary mycosis: lessons taught by two fungi. Immunol Res 2005, 33:53-68.
11. Halwig J.M., Brueske D.A., Greenberger P.A., Dreisin R.B., Sommers H.M. Allergic bronchopulmonary curvulariosis. Am Rev Respir Dis 1985, 132:186-188.
12. Backman K.S., Roberts M., Patterson R. Allergic bronchopulmonary mycosis caused by Fusarium vasinfectum. Am J Respir Crit Care Med 1995, 152:1379-1381.
13. Hendrich D.J., Ellithrope D.B., Lyon F., Hattier P., Salvaggio J.E. Allergic bronchopulmonary helminthosporiosis. Am Rev Respir Dis 1982, 126:935-938.
14. Ogawa H., Fujimura M., Tofuku Y. Allergic bronchopulmonary fungal disease caused by Saccharomyces cerevisiae. JAsthma 2004, 41:223-228.
15. Kamei K., Unno H., Nagao K., Kuriyama T., Nishimura K., Miyaji M. Allergic bronchopulmonary mycosis caused by the basidiomycetous fungus Schizophyllum commune. Clin Infect Dis 1994, 18:305-309.
16. Benatar S.R., Allan B., Hewitson R.P. Allergic bronchopulmonary stemphyliosis. Thorax 1980, 35:515-518.
17. Patterson R., Samuels B.S., Phair J.J., Roberts M. Bronchopulmonary torulopsosis. Int Arch Allergy Appl Immunol 1982, 69:30-33.
18. Knutsen A.P., Bush R.K., Demain J.G., Denning D.W., Dixit A., Fairs A., et al. Fungi and allergic lower respiratory tract diseases. JAllergy Clin Immunol 2012, 129:280-291.
19. Stevens D.A., Moss R.B., Kurup V.P., Knutsen A.P., Greenberger P.A., Judson M.A., et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003, 37(Suppl 3):S225-S264.
20. Mennink-Kersten M.A.S.H., Ruegebrink D., Wasei N., Melchers W.J.G., Verweij P.E. In vitro release by Aspergillus fumigatus of galactofuranose antigens, 1,3-β-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis. JClin Microbiol 2006, 44:1711-1718.
21. Baxter C.G., Moore C.B., Jones A.M., Webb A.K., Denning D.W. IgE-mediated immune responses and airway detection of Aspergillus and Candida in adult cystic fibrosis. Chest 2013, 143:1351-1357.
22. Chauhan B.A., Knutsen A.P., Hutcheson P.S., Slavin R.G., Bellone C.J. Tcell subsets, epitope mapping, and HLA-restriction in patients with allergic bronchopulmonary aspergillosis. JClin Invest 1996, 97:2324-2331.
23. Chauhan B., Santiago L., Kirschmann D.A., Hauptfeld V., Knutsen A.P., Hutcheson P.S., et al. The association of HLA-DR alleles and T cell activation with allergic bronchopulmonary aspergillosis. JImmunol 1997, 159:4072-4076.
24. Chauhan B., Santiago L., Hutcheson P.S., Schwartz H.J., Spitznagel E., Castro M., et al. Evidence for the involvement of two different MHC class II regions in susceptibility or protection in allergic bronchopulmonary aspergillosis. JAllergy Clin Immunol 2000, 106:723-729.
25. Brourad J., Knauer N., Boelle P.-Y., Corvol H., Henrion-Caude A., Flamant C., et al. Influence of interleukin-10 on airways colonization by Aspergillus fumigatus in cystic fibrosis patients. JInfect Dis 2005, 191:1988-1991.
26. Saxena S., Madan T., Shah A., Muralidhar K., Sarma P.A. Association of polymorphisms in the collagen region of SP-A2 with increased levels of total IgE antibodies and eosinophilia in patients with allergic bronchopulmonary aspergillosis. JAllergy Clin Immunol 2003, 111:1001-1007.
27. Miller P.W., Hamosh A., Macej M., Greenberger P.A., MacLean J., Walden S.M., et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis. Am J Hum Genet 1996, 59:45-51.
28. Carvalho A., Pasqualotto A.C., Pitzurra L., Romani L., Denning D.W., Rodrigues F. Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis. JInfect Dis 2008, 197:618-621.
29. Novak N., Yu C.F., Bussmann C., Maintz L., Peng W.M., Hart J., et al. Putative association of a TLR9 promoter polymorphism with atopic eczema. Allergy 2007, 62:766-772.
30. Mahdavinia M., Grammer L.C. Management of allergic bronchopulmonary aspergillosis: a review and update. Ther Adv Respir Dis 2012, 6:173-187.
31. Bains S.N., Judson M.A. Allergic bronchopulmonary aspergillosis. Clin Chest Med 2012, 33:265-281.
32. Agawal R. Allergic bronchopulmonary aspergillosis. Chest 2009, 135:805-826.
33. Agarwal R., Gupta D., Agarwal A.N., et al. Allergic bronchopulmonary aspergillosis: lessons from 126 patients attending chest clinic in north India. Chest 2006, 130:442-448.
34. Greenberger P.A. Allergic bronchopulmonary aspergillosis. JAllergy Clin Immunol 2002, 110:685-692.
35. Poole C.J.M., Wong M. Allergic bronchopulmonary aspergillosis in garden waste (compost) collectors: occupational implications. Occup Med 2013, 63:517-519.
36. Centers for Disease Control. Molds in the environment. Available from: . Accessed October 7, 2012. http://www.cdc.gov/mold/faq.htm.
37. Thompson J.M., Wesley A., Byrnes C.A., Nixon G.M. Pulse intravenous methylprednisolone for resistant allergic bronchopulmonary aspergillosis in cystic fibrosis. Pediatr Pulmonol 2006, 41:164-170.
38. Cohen-Cymbesknah M., Blau H., Shoseyov D., Mei-Zahav M., Efrati O., Armoni S. Intravenous monthly pulse methylprednisolone treatment for ABPA in patients with cystic fibrosis. JCyst Fibros 2009, 8:253-257.
39. Lebrun-Vignes B., Corbrion Archer V., Diquet B., Levron J.C., Chosidow O., Puech A.J., et al. Effect of itraconazole on the pharmacokinetics of prednisone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol 2001, 51:443-450.
40. Agarwal R., Khan A., Aggarwal A.N., Saikia B., Gupta D., Chakrabarti A. Role of inhaled corticosteroids in the management of serological allergic bronchopulmonary aspergillosis (ABPA). Intern Med 2011, 50:855-860.
41. Wark P.A., Hensley M.J., Saltos N., Boyle M.J., Toneguzzi R.C., Epid G.D., et al. Antiinflammatory effect of itraconazole on stable allergic bronchopulmonary aspergillosis; a randomized control trial. JAllergy Clin Immnol 2003, 111:952-957.
42. Wark P.A., Gibson P.G., Wilson A.J. Azoles for allergic bronchopulmonary aspergillosis associated with asthma. Cochrane Database Syst Rev 2004, 3:CD001108.
43. Haylett A.K., Felton S., Denning D.W., Rhodes L.E. Voriconazole-induced photosensitivity: photobiological assessment of a case series of 12 patients. Br J Dermatol 2012, 168:179-185.
44. Agarwal R., Chakrabarti A., Shah A., Gupta D., Meis J.F., Guleria R., et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of a new diagnostic and classification criteria. Clin Exp Allergy 2013, 43:850-873.
45. Hogan C., Denning D.W. Allergic bronchopulmonary aspergillosis and related allergy syndromes. Semin Resp Crit Care Med 2011, 32:682-692.
46. Moreira A.S., Silva D., Reis Ferraira A., Delgado L. Antifungal treatment in allergic bronchiopulmonary aspergillosis with and without cystic fibrosis: a systematic review. Clin Exper Allergy 2014, 44:1210-1227.
47. Chrishimba L., Niven R.M., Cooley J., Denning D.W. Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. JAsthma 2012, 49:423-433.
48. Lebecque P., Leonard A., Pileete C. Omalizumab for treatment of allergic bronchopulmonary aspergillosis exacerbations in cystic fibrosis patients. Pediatr Pulmonol 2009, 44:546.
49. Kanu A., Patel K. Treatment of allergic bronchopulmonary aspergillosis with cystic fibrosis with anti-IgE antibody (omalizumab). Pediatr Pulmonol 2008, 43:1249-1251.
50. van der Ent C.K., Hoestra H., Rijkers G.T., et al. Successful treatment of ABPA with recombinant anti-IgE antibody. Thorax 2007, 62:267-277.
51. Tille-Lelond I., Germaud P., Leroyer C., Tétu L., Girard F., Devouassoux G., et al. Allergic bronchopulmonary aspergillosis and omalizumab. Allergy 2011, 66:1254-1256.
52. Moss R.B. The use of biologic agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis. Ann NY Acad Sci 2012, 1272:49-57.
53. Lotvall J., Akdis C.A., Bacharier L.B., Bjermer L., Casale T.B., Custovic A., et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. JAllergy Clin Immunol 2011, 127:355-360.